Quick navigation menu :

  1. Go to content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Global Business Websites |
     
  3. Contact us |
  4. Sitemap |
  5. Links |
  6. Help
  1. Font size

    Reduce the font size Increase the font size  
 
 

Diabetes

Contact us

Product information services

To get more information
about our products,
please send us your inquiries.

Content :

Diabetes

Diabetes mellitus is a common condition where blood sugar (glucose) exceeds its normal values, because the body is unable to convert it into energy in the normal way. In almost all cases, this is because the lack of insulin production by the body.
371 million people are currently living with diabetes; by 2035 this will rise to 552 million (International Diabetes Federation, Diabetes Atlas, 5th edition).

 

Two types of diabetes

  • Type 1 diabetes is an autoimmune disease that attacks and destroys the insulin-producing pancreatic beta cells. Patients suffer from a total absence of insulin production and secretion.
  • Type 2 diabetes develops over time as insulin secretion deteriorates. Although the pancreas does produce insulin, quantities produced are insufficient to control glycemia adequately. People who have diabetes are more likely to develop serious health problems such as blindness, renal failure, heart attacks, strokes, impotence and amputation. 194 million cases of diabetics are recorded globally, i.e. six times as many as 15 years ago. Forecasts for 2025 predict 300 million diabetics.

Building upon its long proven history in this field, Sanofi is committed to improving global diabetes management through its integrated offering of treatments and medical devices.

Medicines

Our principal medicinal products in the field of diabetes are:

  • Lantus® (insulin glargine), a long-acting human insulin analog.
  • Apidra® (insulin glulisine) a rapid-acting human insulin analog available as 100 IU /ml Injection Cartridge.
  • Amaryl® (glimepiride), a sulfonylurea-class hypoglycemic available in three different dosages (1mg, 2mg & 3mg tab).
  • Furthermore, other diabetes treatments are currently in clinical development.

Medical devices

  • Lantus® and Apidra® are also available in the form of Lantus SoloSTAR® and ApidraSoloSTAR® injection pens.
  • Sanofi has established agreements with several innovative companies to make new therapeutic solutions available to patients.

Update: April 10, 2014